S. 993 · 118th Congress · Senate

Combating Illicit Xylazine Act

Active· Committee on Banking, Housing, and Urban Affairs. Hearings held.
Introduced
Mar 28, 23
Passed Senate
Pending
Passed House
Pending
Sent to President
Pending
Signed into Law
Pending

Executive Summary

Combating Illicit Xylazine Act

This bill criminalizes the illicit use of xylazine. (Xylazine, also known as Tranq, is a sedative that is approved for use in animals. The Drug Enforcement Administration (DEA) has reported an increase in the trafficking of fentanyl mixed with xylazine.)

Specifically, the bill establishes criminal penalties for manufacturing, distributing, or dispensing, or possessing with intent to manufacture, distribute, or dispense, xylazine for illicit use (i.e., for use in humans) in accordance with the penalties for schedule III substances (up to 10 years imprisonment or, if death or serious bodily injury occurs, up to 15 years imprisonment, as well as criminal fines).

In addition, the DEA must coordinate with the Food and Drug Administration to report on the prevalence of the illicit use of xylazine, including associated supply chains. The bill also declares the illicit use of xylazine as an emerging drug threat.

Action Timeline

3
  1. JAN 11, 2024Committee

    Committee on Banking, Housing, and Urban Affairs. Hearings held.

  2. MAR 28, 2023IntroReferral

    Introduced in Senate

  3. MAR 28, 2023IntroReferral

    Read twice and referred to the Committee on the Judiciary.

Committees

2

Banking, Housing, and Urban Affairs Committee

ssbk00

Referred: Jan 11, 2024

Active

Judiciary Committee

ssju00

Referred: Mar 28, 2023

Active